Watchlist Price Alert

Pacific Biosciences of Ca... (PACB)

NASDAQ: PACB · Real-Time Price · USD

1.00

-0.03 (-2.91%)

At close: Jun 05, 2025, 9:57 AM

-2.91% (1D)

Bid	0.73
Market Cap	300.08M
Revenue (ttm)	152.36M
Net Income (ttm)	-657.75M
EPS (ttm)	-2.74
PE Ratio (ttm)	-0.36
Forward PE	-1.94
Analyst	Hold

Ask	1.27
Volume	1,091,951
Avg. Volume (20D)	8,691,600
Open	1.01
Previous Close	1.03
Day's Range	0.99 - 1.03
52-Week Range	0.85 - 2.72
Beta	2.10

About PACB

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PACB

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PACB stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

-6.67%

Pacific Biosciences shares are trading lower. The ... Unlock content with Pro Subscription

1 month ago

+20.83%

Pacific Biosciences of California shares are trading higher after the company reported its Q1 prelimary revenue results.

News

1 week ago · zacks.com

All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy

Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 week ago · zacks.com

PacBio Stock Slips Despite New China Distribution Deal With Haorui

PACB expands reach in China through Haorui Gene partnership, bringing HiFi sequencing to new clinical labs and boosting precision medicine access nationwide.

3 weeks ago · zacks.com

PACB Stock May Rise Following the Deal With Chulalongkorn University

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

3 weeks ago · zacks.com

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

3 weeks ago · zacks.com

Pacific Biosciences (PACB) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Pacific Biosciences (PACB) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metri...

3 weeks ago · seekingalpha.com

Pacific Biosciences of California, Inc. (PACB) Q1 2025 Earnings Call Transcript

Pacific Biosciences of California, Inc. (NASDAQ:PACB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance & Investor Relations Christ...

3 weeks ago · zacks.com

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.26 per share a year ago.